Legend Biotech says CARVYKTI posts about $710 million net trade sales in quarter ended Sept. 30, 2026

By Public Technologies
  • Legend Biotech flagged preliminary CARVYKTI net trade sales of about $710 million for the quarter ended Sept. 30, 2026.
  • Figure was provided by partner Janssen; Legend Biotech has not independently verified the amount.
  • No percentage changes were disclosed in the update.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006593), on October 13, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk